Leading international competence recruited to the board of Hamlet Pharma
As previously announced, the Extraordinary General Meeting of Hamlet Pharma held on the 4th of March, elected Professor Bill Hansson to the board of Hamlet Pharma.
Bill Hansson was until recently Vice President of the Max Planck Society. In this capacity he facilitated the progress of science in Germany and internationally and during his leadership, the organization has flourished, as illustrated e.g. by the recent Nobel Prize awards. Bill Hansson has also overseen the translation of scientific innovations for public and commercial use and spearheaded a new human resources and communication strategy for the MPS. Bill Hansson is an internationally recognized scientist in the field of biology and his extensive academic leadership includes his present directorship at the Max Planck Institute for Chemical Ecology in Jena. Bill Hansson was recently awarded the Federal Cross of Merit 1st Class by the President of Germany.
Hamlet Pharma would also like to thank Rolf Carlsson for his role on the board of directors.
Rolf Carlsson was elected to the board at the AGM in November 2019 and has contributed to the development of the company. Rolf Carlsson is running a successful head hunting business, which now is expanding, and he will focus on this task. Rolf Carlsson’s experience of life science has stimulated discussions about the vision and strategy of the company. We thank him for his contributions.
For more information, please contact
Catharina Svanborg, Chairperson of the board, Hamlet Pharma, +46 709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat, and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.